Amylin Pharmaceuticals And Eli Lilly And Company Statement On FDA's BYETTA(R) (Exenatide) Injection Update

Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection. "The FDA update issued today aligns with the BYETTA label approved last week. The current label reflects our understanding of post-marketing reports of renal events and provides physicians with updated guidance about appropriate use in patients with renal conditions.